Human Interleukin-11

PreclinicalProtein / enzyme

JJun Wang

Human Interleukin-11 is one of 35 small molecule programs targeting Thrombocytopenia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ThrombocytopeniaActive, not recruiting

ThrombocytopeniaPreclinical

Active, not recruiting

Competition

Competitive Landscape

40 competitors in Thrombocytopenia

#DrugCompanyPhaseTrials

Doptelet

AAkarx

Approved

18 2

Medrol

Pfizer

Approved

2 3

Innohep

Jazz Pharmaceuticals

Approved

1 4

Lovenox

Sanofi

Approved

1 5

Fragmin

Pfizer

Approved

1 6

Promacta

GSK

Phase 3

13 7

Angiomax

BBaxter Healthcare Corporation

Approved

2 8

Actemra

CCelltrion

Approved

1 9

Acetadote

AArbor Pharmaceuticals, Inc.

Rayos

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

N/ANot yet recruiting

Thrombocytopenia

NCT07185893

Clinical

Trials by Indication[1]

Thrombocytopenia1 trial

A Multicenter, Open-label, Randomized Controlled Trial Evaluating the Efficacy and Safety of Romiplostim N01 in the Treatment of Thrombocytopenia Associated With Concurrent/Sequential Chemoradiotherapy and Chemotherapy Combined With/Without Immunotherapy in Solid Tumors

Not yet recruiting·JJun Wang·N/A·NCT07185893·106 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Human Interleukin-11. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Human Interleukin-11 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Human Interleukin-11. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jun Wang company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Preclinical[1]
Company: JJun Wang

Human Interleukin-11

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Thrombocytopenia1 trial

References

Drug Info

Quick Facts

Related News